1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Novacyt S.A.

Novacyt S.A.

0.46
EUR
0.00
(0.00%)
42.90MMarket Cap
Apr 29Next Earn
Novacyt S.A.
GETTEX:NYZ
(Gettex)

Recent

price

0.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
0.23
0.27
329.93
0.8
0.71
0.67
0.44
0.33
0.25
4.07
1.31
0.3
0.15
0.28
0.28
- -
Revenue per Share
-0.18
-0.14
-284.76
-0.69
-1.11
-0.34
-0.19
-0.11
-0.13
1.94
-0.14
-0.36
-0.4
-0.59
-0.32
- -
Basic EPS, GAAP
-0.2
-0.2
-505.62
-0.47
-0.49
-0.19
-0.2
-0.05
-0.03
1.49
0.16
-0.2
-0.33
-0.16
-0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.23
0.4
0.64
2.2
0.8
0.74
0.52
0.48
0.21
2.13
2.01
1.63
1.24
0.68
0.33
0.68
Book Value per Share
-0.36
0.17
0.34
0.01
- -
-0.17
0.08
-0.02
-0.08
1.82
1.79
1.49
0.79
0.39
0.28
0.39
Tangible Book Value per Share
3
3
- -
4
7
12
23
38
46
68
71
71
71
71
71
71
Basic Weighted Avg Shares
1
1
1
4
5
8
10
12
11
277
93
21
11
20
20
- -
Sales/Revenue/Turnover
-75.02
-51.94
-120.62
-53.16
-34.12
-26.97
-0.27
-3.8
-9.24
63.1
1.53
-74.5
-149.02
17.14
-61.8
- -
Operating Margin (%)
- -
- -
- -
- -
5
1
1
1
2
8
8
8
10
- -
19
- -
Depreciation Expense
- -
- -
-1
-3
-8
-4
-4
-4
-6
132
-10
-26
-28
-42
-23
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.83
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-74.93
-50.47
-86.31
-86.43
-156.41
-51.55
-42.69
-34.53
-50.13
47.77
-10.51
-122.29
-266.38
-212.73
-114.25
- -
Profit Margin (%)
- -
1
1
1
1
-1
2
- -
- -
131
120
103
57
33
22
33
Working Capital
- -
- -
- -
- -
1
2
1
2
8
2
1
- -
12
11
10
11
LT Debt
-1
1
2
16
6
13
20
18
12
151
142
115
87
48
23
48
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
130.07
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
152.89
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-56.13
-34.49
-70.16
-44.54
-26.36
-22.59
-37.55
162.31
-6.65
-20.02
-27.95
-61.81
-64.23
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
12
12
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
71
71
71
Market Capitalization
44
32
35

Working Capital

GBP

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
86
55
39
Cash, Cash Equivalents & STI
44
33
30
Accounts Receivable, Net
27
3
3
Inventories
3
3
2
Total Current Liabilities
30
14
6
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
110.29%
-29.05%
-51.19%
Free Cash Flow
-933.19%
-62.04%
-10.21%
Net Income, GAAP
-234.15%
13.9%
-45.2%
Sales/Revenue/Turnover
231.78%
-21.31%
2.03%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
11
2024
- -
- -
20
2025
- -
- -
20

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.4
2024
- -
- -
-0.59
2025
- -
- -
-0.32

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Novacyt S.A. Novacyt S.A. is an international molecular diagnostics company that develops, manufactures and commercialises a broad portfolio of integrated technologies, assays and services focused on delivering genomic medicine and end-to-end workflows from sample to result across human health, animal health and environmental sectors. The company operates through three primary business segments: Clinical, offering in vitro diagnostic products in reproductive health including non-invasive prenatal testing (NIPT), cystic fibrosis and rapid aneuploidy tests, precision medicine such as the DPYD genotyping assay for chemotherapy toxicity screening, and infectious diseases like the Winterplex multiplex respiratory PCR panel; Instrumentation, featuring next-generation Ranger Technology platforms for automated DNA sample preparation and target enrichment, genesig q16/q32 and MyGo real-time quantitative PCR (qPCR) instruments, and the Co-Prep ES automated extraction system; and Research Use Only (RUO), providing high-performance qPCR assays, custom development, whole genome/exome sequencing services and workflows for life sciences, agriculture, veterinary and pharmaceutical research. Novacyt S.A. serves clinical laboratories, research institutions, global health organisations and pharmaceutical companies, with a commercial presence in over 65 countries including key markets in Europe, Asia-Pacific, the Middle East, the Americas and Africa. Founded in 2006 and headquartered in Vélizy-Villacoublay, France, the company maintains offices in the United Kingdom (Eastleigh, Manchester and Stokesley), Singapore, the United States and Canada; it lists on the London Stock Exchange AIM (NCYT) and Euronext Growth Paris (ALNOV.PA). Subsidiaries and integrated businesses include Primerdesign for qPCR kits and reagents, Yourgene Health for NIPT and precision medicine solutions, IT-IS International for PCR instrumentation, Microgen Bioproducts and Lab21 Healthcare. In recent developments, Novacyt S.A. completed the strategic acquisition of Yourgene Health in September 2023 for £16.7 million, enhancing its diagnostics scale, diversifying revenues and accelerating growth in reproductive health and Ranger Technology, with £5 million in cost synergies achieved ahead of schedule within 18 months. The company realised an additional £3 million in annualised EBITDA improvements through 2024-2025 site consolidations, including closure of IT-IS International operations, relocation of Canadian manufacturing and Primer Design facilities, alongside disposal of its Taiwanese laboratory business. Further advancements include IVDR certification for the DPYD assay in 2023 and submission for cystic fibrosis QF-PCR, launch of MagBench automated extraction for NIPT in Asia-Pacific, a co-marketing partnership with PacBio for Ranger Technology compatibility, support for a new NIPT lab in Colombia operational since October 2024, appointment of Lyn Rees as CEO and Steve Gibson as CFO in 2024, and planned launches of four new products in 2025 with £2 million additional R&D investment targeting reproductive health, precision medicine and instrumentation.

Company News

Company News APIChatGPT